top of page
pic3.jpg

Publications

Peer reviewed:
Blinman P, McLachlan S, Nowak AK, Duric V, Brown C, Wright G, Millward M, Fong K, Stockler M. (2011) Lung cancer clinicians’ preferences for adjuvant chemotherapy in non-small cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), p231

Blinman P, Alam M, McLachlan S, Duric V, Stockler M. (2010) Patients’ preferences for chemotherapy in non-small cell lung cancer: a systematic review. Lung Cancer, 69(2), p141-7

 

Blinman P, Duric V, Nowak AK, Beale P, Clarke S, Briscoe K, Boyce A, Goldstein D, Hudson M, Stockler M. (2010) Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European journal of cancer, 69(2), p141-7

 

Duric VM, Butow PN, Sharpe L, Heritier S, Boyle F, Beith J, Wilcken NRC, Coates AS, Simes RJ, Stockler MR. (2008) Comparing patients’ and their partners’ preferences for adjuvant chemotherapy in early breast cancer  Patient Education and Counseling, 72, 239-245

Gainford MC, Stockler MR, Butow PN, Boyle F, Sullivan A, Beale P, Pendlebury S, Nowak AK, Duric VM, (2008) What caused your cancer? A survey of patients with early breast and bowel cancer  Journal of Clinical Oncology, 26(15_suppl): 9563-9563

Duric V, Francis P, Simard-Lebrun J, Chan A, Chirgwin J, Harvey VJ, Simes J, Coates AS, Stockler M (2007) Preferences for adjuvant chemotherapy (ACT) in early breast cancer: The benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile  Journal of Clinical Oncology, 25(18_suppl): 6528-6528

 

Duric VM, Butow PN, Sharpe L, Boyle F, Beith J, Wilcken NRC, Heritier S, Coates AS, Simes RJ, Stockler MR. (2007) Psychosocial factors and patients’ preferences for adjuvant chemotherapy in early breast cancer  Psycho-oncology, 16, 48-59

Joseph D, Nowak AK, Corica T, Saunders C, Herbert C, Bulsara M, Duric V, (2006) Patient perferences for adjuvant radiotherapy in early breast cancer- an Australian sub-study of the pilot TARGIT study European journal of the European Society of Surgucan Oncology and the British Association of Surgical Oncology 32(1):S79-S80

Greimel ER, Kuljanic-Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, Chie WC, Nordin A, Bjelic-Radisic V, Wydra D on behalf of the European Organisation for Research and Treatment  of Cancer Quality of Life Group. (2006) The European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Cervical Cancer Module- EORTC QLQ-CX24 Cancer, 107(8), 1812-1822.

 

Duric VM, Fallowfield LJ, Saunders C, Houghton J, Coates AS, Stockler MR. (2005) Patients’ preferences for adjuvant endocrine therapy: what makes it worthwhile? British Journal of Cancer, 93(12), 1319-1323.

               

Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates A, Simes RJ.  (2005) Patients’ preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Annals of Oncology,16(11), 1786-1794.

 

Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander M. (2005) What survival benefits do premenopausal early breast cancer patients need to make adjuvant endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588.

 

Duric V, Butow P, Sharpe L, Lobb E, Meiser B, Barratt A., Tucker K. (2003) Reducing psychological distress in a genetic counseling consultation for breast cancer. Journal of Genetic Counseling, 12(3), 243-264.

 

Duric, V. & Stockler, M. (2001) Patients’ preferences for adjuvant chemotherapy in early breast cancer. A review of what makes it worthwhile. Lancet Oncology, 2(11), 691-697.

 

Spence, S; Duric, V.; Roeder, U. (1996) Performance Realism in Test-Anxious Students. Anxiety, Stress, and Coping, 9, 339-355.

 

 

 

Book chapter:

Stockler M, Duric V, Coates A. Patients’ Preferences: What makes treatments worthwhile? Pages 925-944. Book chapter in: Breast Cancer Management in the Era of Molecular Medicine - towards tailored approaches Editors: Piccart M, Wood WC, Hung M-C, Solin LJ & Cardoso F. Springer-Verlag Berlin Heidelberg 2006

 

 

Selected conferences:

Duric V, Francis P, Simard-Lebrun J, Chan A, Chirgwin J, Harvey V, Sullivan A, Simes R, Coates AS, Stockler M; PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY BREAST CANCER: THE BENEFITS NEEDED TO MAKE EXTENDED TREATMENT WITH DOCETAXEL, DOXORUBICIN, AND CMF WORTHWHILE American Society of Clinical Oncologists Annual Scientific Meeting, Chicago 2007

 

Duric V, Stockler MR, Butow P, Sharpe L, Heritier S, Beith J, Boyle F, Wilcken N, Coates A, Simes RJ COMPARING PATIENTS’ AND THEIR PARTNERS’ PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER American Society of Clinical Oncologists Annual Scientific Meeting,- Orlando 2005

 

Duric V, Stockler M, Butow P, Sharpe L MAKING SENSE OF PATIENTS’ PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY BREAST CANCER (EBC): WHAT MAKES IT WORTHWHILE, WHO DECIDES AND WHY? International Society for Quality of Life Research Annual Meeting, Hong Kong. 2004- New Investigator Scholarship

 

Duric V, Sharpe L, Stockler M, Butow P, Dhillon H, Boyle F, Sullivan A, Beith J, Wilcken N PSYCHOSOCIAL PREDICTORS OF DECISIONS ABOUT ADJUVANT CHEMOTHERAPY AMONG WOMEN WITH EARLY BREAST CANCER. International Psycho-Oncology Society- 6th World Congress Psycho-oncology, Banff,Canada. 2003

 

Duric V, Stockler M, Butow P, Sharpe L, Dhillon H, Boyle F, Sullivan A, Beith J, Wilcken N

WHAT DO PATIENTS AND THEIR PARTNERS THINK MAKES ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER WORTHWHILE?  International Psycho-Oncology Society- 6th World Congress in Psycho-Oncology, Banff, Canada. 2003

       

Stockler, M; Duric, V; Simes, RJ; Dhillon, H; Beith, J; Sullivan, A; Coates, A
PATIENTS’ PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER: WHAT MAKES IT WORTHWHILE? American Society of Clinical Oncologists- San Francisco. May, 2001

bottom of page